Does the media refer more to PGEN or IMMX?

In the previous week, Precigen had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 8 mentions for Precigen and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat Precigen's score of 0.52 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IMMX or KLRA?

Immix Biopharma is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.88 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is IMMX or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Kailera Therapeutics N/A N/A N/A

Does the media prefer IMMX or KLRA?

In the previous week, Kailera Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Kailera Therapeutics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat Kailera Therapeutics' score of -0.05 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CDNA or IMMX?

CareDx has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $379.80M 6.62 -$21.35M $2.07 23.48 Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Does the media favor CDNA or IMMX?

In the previous week, CareDx and CareDx both had 3 articles in the media. CareDx's average media sentiment score of 1.45 beat Immix Biopharma's score of 1.19 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, COAG or IMMX?

Immix Biopharma is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Is COAG or IMMX more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Immix Biopharma N/A -38.44% -34.72%

Does the media prefer COAG or IMMX?

In the previous week, Immix Biopharma had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 3 mentions for Immix Biopharma and 2 mentions for Hemab Therapeutics. Immix Biopharma's average media sentiment score of 1.19 beat Hemab Therapeutics' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADMA or IMMX?

In the previous week, ADMA Biologics had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for ADMA Biologics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat ADMA Biologics' score of 0.15 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immix Biopharma (IMMX) Competitors

$13.66 +0.50 (+3.80%)

As of 08/21/2026 04:00 PM Eastern

Compare

IMMX vs. PGEN, KLRA, CDNA, COAG, and ADMA

Should you buy Immix Biopharma stock or one of its competitors? Immix Biopharma's main competitors and comparable companies include Precigen (PGEN), Kailera Therapeutics (KLRA), CareDx (CDNA), Hemab Therapeutics (COAG), and ADMA Biologics (ADMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immix Biopharma compare to Precigen?

Precigen (NASDAQ:PGEN) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Precigen had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 8 mentions for Precigen and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat Precigen's score of 0.52 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Immix Biopharma	N/A	-38.44%	-34.72%

Immix Biopharma has lower revenue, but higher earnings than Precigen. Immix Biopharma is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	265.17	-$250.64M	-$1.04	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Precigen presently has a consensus price target of $14.50, suggesting a potential upside of 101.39%. Immix Biopharma has a consensus price target of $21.29, suggesting a potential upside of 55.83%. Given Precigen's stronger consensus rating and higher probable upside, equities analysts plainly believe Precigen is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

33.5% of Precigen shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 41.4% of Precigen shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

Summary

Precigen beats Immix Biopharma on 11 of the 16 factors compared between the two stocks.

How does Immix Biopharma compare to Kailera Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Kailera Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Kailera Therapeutics	N/A	N/A	N/A

Immix Biopharma is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Immix Biopharma currently has a consensus target price of $21.29, suggesting a potential upside of 55.83%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 148.98%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Kailera Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Kailera Therapeutics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat Kailera Therapeutics' score of -0.05 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Kailera Therapeutics beats Immix Biopharma on 7 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to CareDx?

CareDx (NASDAQ:CDNA) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

11.3% of Immix Biopharma shares are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CareDx has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

CareDx has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	6.62	-$21.35M	$2.07	23.48
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

In the previous week, CareDx and CareDx both had 3 articles in the media. CareDx's average media sentiment score of 1.45 beat Immix Biopharma's score of 1.19 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has a net margin of 24.23% compared to Immix Biopharma's net margin of 0.00%. CareDx's return on equity of 2.87% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Immix Biopharma	N/A	-38.44%	-34.72%

CareDx currently has a consensus price target of $47.75, indicating a potential downside of 1.77%. Immix Biopharma has a consensus price target of $21.29, indicating a potential upside of 55.83%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

CareDx beats Immix Biopharma on 10 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Immix Biopharma had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 3 mentions for Immix Biopharma and 2 mentions for Hemab Therapeutics. Immix Biopharma's average media sentiment score of 1.19 beat Hemab Therapeutics' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hemab Therapeutics presently has a consensus price target of $51.40, indicating a potential upside of 4.56%. Immix Biopharma has a consensus price target of $21.29, indicating a potential upside of 55.83%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Hemab Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Immix Biopharma	N/A	-38.44%	-34.72%

Immix Biopharma is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Summary

Immix Biopharma beats Hemab Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Immix Biopharma compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Immix Biopharma (NASDAQ:IMMX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

ADMA Biologics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics presently has a consensus target price of $18.67, suggesting a potential upside of 89.70%. Immix Biopharma has a consensus target price of $21.29, suggesting a potential upside of 55.83%. Given ADMA Biologics' higher probable upside, research analysts plainly believe ADMA Biologics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ADMA Biologics has a net margin of 32.98% compared to Immix Biopharma's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Immix Biopharma	N/A	-38.44%	-34.72%

ADMA Biologics has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$512.28M	4.30	$146.93M	$0.70	14.06
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

In the previous week, ADMA Biologics had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for ADMA Biologics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat ADMA Biologics' score of 0.15 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Immix Biopharma on 11 of the 15 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$977.22M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-15.52	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	4.27	16.80	13.05	6.20
Net Income	-$29.44M	-$12.50M	$3.47B	$348.59M
7 Day Performance	24.52%	3.29%	2.09%	0.08%
1 Month Performance	55.23%	8.23%	6.64%	3.88%
1 Year Performance	523.74%	55.05%	25.02%	16.98%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	2.8217 of 5 stars	$13.66 +3.8%	$21.29 +55.8%	+523.7%	$977.22M	N/A	N/A	9	Positive News
PGEN Precigen	3.4796 of 5 stars	$6.85 -0.1%	$14.50 +111.7%	+72.2%	$2.45B	$85.72M	N/A	190	Options Volume
KLRA Kailera Therapeutics	1.4442 of 5 stars	$18.59 -1.5%	$42.75 +130.0%	N/A	$2.44B	N/A	N/A	145	News Coverage
CDNA CareDx	2.9773 of 5 stars	$47.31 +0.2%	$47.75 +0.9%	+274.8%	$2.44B	$379.80M	22.86	740	Positive News
COAG Hemab Therapeutics	2.1081 of 5 stars	$53.48 +3.4%	$51.40 -3.9%	N/A	$2.42B	N/A	N/A	72

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. PGEN, KLRA, CDNA, COAG, and ADMA

How does Immix Biopharma compare to Precigen?

Summary

How does Immix Biopharma compare to Kailera Therapeutics?

Summary

How does Immix Biopharma compare to CareDx?

Summary

How does Immix Biopharma compare to Hemab Therapeutics?

Summary

How does Immix Biopharma compare to ADMA Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. PGEN, KLRA, CDNA, COAG, and ADMA

How does Immix Biopharma compare to Precigen?

Does the media refer more to PGEN or IMMX?

Is PGEN or IMMX more profitable?

Which has stronger earnings and valuation, PGEN or IMMX?

Do analysts prefer PGEN or IMMX?

Do institutionals & insiders hold more shares of PGEN or IMMX?

Which has more volatility & risk, PGEN or IMMX?

Summary

How does Immix Biopharma compare to Kailera Therapeutics?

Is IMMX or KLRA more profitable?

Which has better valuation and earnings, IMMX or KLRA?

Do analysts prefer IMMX or KLRA?

Does the media prefer IMMX or KLRA?

Do institutionals & insiders have more ownership in IMMX or KLRA?

Summary

How does Immix Biopharma compare to CareDx?

Do institutionals and insiders have more ownership in CDNA or IMMX?

Which has more volatility and risk, CDNA or IMMX?

Which has stronger valuation and earnings, CDNA or IMMX?

Does the media favor CDNA or IMMX?

Is CDNA or IMMX more profitable?

Do analysts prefer CDNA or IMMX?

Summary

How does Immix Biopharma compare to Hemab Therapeutics?

Does the media prefer COAG or IMMX?

Do institutionals & insiders believe in COAG or IMMX?

Do analysts recommend COAG or IMMX?

Is COAG or IMMX more profitable?

Which has preferable valuation & earnings, COAG or IMMX?

Summary

How does Immix Biopharma compare to ADMA Biologics?

Which has more risk & volatility, ADMA or IMMX?

Do institutionals and insiders hold more shares of ADMA or IMMX?

Do analysts recommend ADMA or IMMX?

Is ADMA or IMMX more profitable?

Which has higher earnings and valuation, ADMA or IMMX?

Does the media favor ADMA or IMMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools